{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:14:51Z","timestamp":1789236891580,"version":"build-2803163510"},"reference-count":49,"publisher":"National Academy of Sciences","issue":"22","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":184,"URL":"https:\/\/www.pnas.org\/site\/aboutpnas\/licenses.xhtml"}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2020,6,2]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Epstein\u2013Barr virus (EBV)-associated diseases represent a major cause of morbidity worldwide, accounting for at least 1.5% of the global cancer burden, and contributing to autoimmunity. Viral reactivation from latency is associated with an increased risk of EBV-driven cancers, and thus may be a target for disease prevention. Anti-EBV agents that are safe, effective, and suitable for continuous long-term treatment are needed to address questions of whether suppression of lytic reactivation can reduce the incidence of EBV-associated diseases. Here we report that tenofovir disoproxil fumarate and tenofovir alafenamide, drugs with excellent safety profiles used for HIV prophylaxis, are potent inhibitors of EBV. This study identifies compounds that enable clinical investigations of antiviral therapy for EBV in efforts toward disease prevention.<\/jats:p>","DOI":"10.1073\/pnas.2002392117","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T20:17:39Z","timestamp":1589487459000},"page":"12368-12374","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":68,"title":["Tenofovir prodrugs potently inhibit Epstein\u2013Barr virus lytic DNA replication by targeting the viral DNA polymerase"],"prefix":"10.1073","volume":"117","author":[{"given":"Natalia C.","family":"Drosu","sequence":"first","affiliation":[{"name":"Institute for Medical Engineering &amp; Science, Massachusetts Institute of Technology, Cambridge, MA 02139;"},{"name":"Health Sciences &amp; Technology, Harvard Medical School, Boston, MA 02115;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-7156","authenticated-orcid":false,"given":"Elazer R.","family":"Edelman","sequence":"additional","affiliation":[{"name":"Institute for Medical Engineering &amp; Science, Massachusetts Institute of Technology, Cambridge, MA 02139;"},{"name":"Health Sciences &amp; Technology, Harvard Medical School, Boston, MA 02115;"},{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, MA 02115;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5016-0756","authenticated-orcid":false,"given":"David E.","family":"Housman","sequence":"additional","affiliation":[{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"e_1_3_3_1_2","first-page":"1898","volume-title":"Fields Virology","author":"Longnecker R. M.","year":"2013","unstructured":"R. M. Longnecker, E. Kieff, J. I. Cohen, \u201cEpstein-Barr virus\u201d in Fields Virology, D. M. Knipe, P. M. Howley, Eds. (Lippincott Williams & Wilkins, Philadelphia, PA, ed. 6, 2013), pp. 1898\u20131959.","edition":"6"},{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-013023"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-3-319-22822-8_15","volume-title":"Epstein-Barr Virus","author":"Ascherio A.","year":"2015","unstructured":"A. Ascherio, K. L. Munger, \u201cEBV and autoimmunity\u201d in Epstein-Barr Virus, C. M\u00fcnz, Ed. (Springer International Publishing, Cham, Switzerland, 2015), Vol. 1, pp. 365\u2013385."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01512-10"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.22.13993-14003.2005"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/274756a0"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.19.9131"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903163201103"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603609"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019100"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109270-00006"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199709270-00010"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02487-09"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.9.7271-7277.1999"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90127-9"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(82)90014-6"},{"key":"e_1_3_3_17_2","first-page":"59","article-title":"Drugs for non-HIV viral infections","volume":"5","year":"2007","unstructured":"Drugs for non-HIV viral infections. Treat. Guidel. Med. Lett. 5, 59\u201370 (2007).","journal-title":"Treat. Guidel. Med. Lett."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1877"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.04.015"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: A randomised, double-blind, active-controlled phase 3 trial","volume":"3","author":"Gallant J. E.","year":"2016","unstructured":"J. E. Gallant ., Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: A randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 3, e158\u2013e165 (2016).","journal-title":"Lancet HIV"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2011.08.015"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01152-15"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix029"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/272583a0"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5716"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.9.2762"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.4.569-596.2003"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1599"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007070"},{"key":"e_1_3_3_31_2","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"Young L. S.","year":"2007","unstructured":"L. S. Young, J. R. Arrand, P. G. Murray, \u201cEBV gene expression and regulation\u201d in Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, A. Arvin, Ed. . (Cambridge University Press, 2007)."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep11767"},{"key":"e_1_3_3_33_2","volume-title":"Reviews in Antiviral Therapy and Infectious Diseases: 20th International Workshop on Clinical Pharmacology of HIV Hepatitis & Other Antiviral Drugs","author":"Yager J.","year":"2019","unstructured":"J. Yager ., \u201cTenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy\u201d in Reviews in Antiviral Therapy and Infectious Diseases: 20th International Workshop on Clinical Pharmacology of HIV Hepatitis & Other Antiviral Drugs, (Virology Education, Noordwijk, The Netherlands, 2019)."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408573200"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320301"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01236-10"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01834-15"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90055-9"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410512"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.1.114-128.2003"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.170"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2007.02.002"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12833"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3337"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2438-2441.2003"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000167155.44980.e8"},{"key":"e_1_3_3_48_2","unstructured":"US Food and Drug Administration FDA briefing document: Meeting of the Antimicrobial Drugs Advisory Committee August 7 2019. www.fda.gov\/media\/129607\/download. Accessed 6 March 2020."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185128"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.2002392117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T07:12:58Z","timestamp":1649833978000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.2002392117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":49,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,6,2]]}},"alternative-id":["10.1073\/pnas.2002392117"],"URL":"https:\/\/doi.org\/10.1073\/pnas.2002392117","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"2020-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}